Transforming growth factor beta receptor I (TGFBR1) (TGFBR1)

Transforming growth factor beta receptor I (TGFBR1), commonly referred to as ALK5, is a transmembrane serine/threonine kinase that serves as a fundamental component of the TGF-beta signaling cascade [1, 2]. The receptor is activated following the binding of TGF-beta ligands to the type II receptor (TGFBR2), which then phosphorylates TGFBR1 to initiate downstream signaling through SMAD2 and SMAD3 proteins [1, 5]. This pathway is essential for regulating a wide array of biological processes, including cell proliferation, differentiation, apoptosis, and the production of the extracellular matrix [2, 5]. In the context of disease, TGFBR1 is frequently implicated in the progression of various cancers, where it promotes epithelial-mesenchymal transition (EMT), metastasis, and an immunosuppressive tumor microenvironment [5]. It also plays a central role in fibrotic disorders of the liver, lungs, and kidneys by driving excessive collagen production [2]. Pharmacological targeting of TGFBR1 primarily involves small-molecule kinase inhibitors designed to block its intracellular signaling, though clinical development has faced challenges due to potential toxicities such as heart valve dysfunction and skin lesions [3, 4]. Sources: [1] UniProt (P36897) [2] NCBI Gene (7046) [3] DrugBank Online (Galunisertib) [4] PubMed (PMID: 25135958) [5] PubMed (PMID: 28232568)

Other names

ALK5Activin receptor-like kinase 5SKR3ACVRLK4TGF-beta receptor type ITbetaR-I

Small molecule kinase inhibition (ATP-competitive inhibition of the serine/threonine kinase domain), blocking phosphorylation of SMAD2 and SMAD3.